A Retrospective Single Institution Study Investigating the Efficacy of Biosimilar G-CSF Compared to the Original G-CSF among Patients who underwent Stem cell mobilization.
Latest Information Update: 23 Jan 2019
Price :
$35 *
At a glance
- Drugs Filgrastim (Primary)
- Indications Amyloidosis; Febrile neutropenia; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Stem cell mobilisation
- Focus Therapeutic Use
- 23 Jan 2019 New trial record
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology